Liu Xi, Wang Yiding, Wang Zhe, Shao Bo, Liu Qiang, Li Changqi, Lv Chengcheng, Bi Huan, Shan Guangyi, Fu Shui, Chen Ang, Zeng Yu
Cancer Hospital of China Medical UniversityCancer Hospital of Dalian University of TechnologyLiaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, People's Republic of China.
Int Urol Nephrol. 2025 Mar 9. doi: 10.1007/s11255-025-04446-w.
To evaluate the efficacy of integrating en bloc resection, endoscopic submucosal dissection (ESD), and submucosal injection of chemotherapeutic agents with TURBT (cESD-TURBT).
This retrospective observational study was conducted on patients diagnosed with stage cTa-T1 bladder cancer who received TURBT between December 2020 and July 2023 at Liaoning Cancer Hospital. The participants were grouped on the basis of the type of treatment they received: cESD-TURBT (n = 118) or conventional TURBT (cTURBT, n = 105). Hydroxycothecin is the chemotherapeutic agent used for submucosal injections. The primary outcome was the recurrence-free survival (RFS) of the treated patients with bladder cancer. The secondary outcomes included disease recurrence within one year, operation duration, length of postoperative hospitalization, and complication rates. Statistical analyses were performed via appropriate tests, with a threshold of P < 0.05 defined as statistically significant.
Compared with the cTURBT cohort, the cESD-TURBT cohort demonstrated increased RFS, with a median follow-up of 775 days (interquartile range [IQR] 414-1040). The recurrence rate in the cESD-TURBT cohort was 18.6% (22/118), whereas it was 39.1% (41/105) in the cTURBT cohort, with a log-rank hazard ratio of 0.49 (95% CI 0.29-0.82; p = 0.0053). Furthermore, cESD-TURBT resulted in fewer postoperative complications than did cTURBT, markedly reducing the occurrence of complications, such as the obturator reflex (1.7% vs. 8.6%, p = 0.03). The difference in operation time was not statistically significant, with a cESD-TURBT of 49.0 ± 21.0 min and a cTURBT of 44.3 ± 23.8 min (p = 0.127).
Our analysis revealed that, compared with cTURBT, cESD-TURBT significantly lowers recurrence rates and is associated with fewer postoperative complications. Our study revealed that cESD-TURBT is superior to cTURBT for bladder tumor removal.
评估整块切除、内镜黏膜下剥离术(ESD)以及黏膜下注射化疗药物联合经尿道膀胱肿瘤切除术(cESD-TURBT)的疗效。
本回顾性观察研究针对2020年12月至2023年7月期间在辽宁省肿瘤医院接受经尿道膀胱肿瘤切除术的cTa-T1期膀胱癌患者进行。参与者根据所接受的治疗类型分组:cESD-TURBT组(n = 118)或传统经尿道膀胱肿瘤切除术(cTURBT,n = 105)。羟基喜树碱是用于黏膜下注射的化疗药物。主要结局是治疗的膀胱癌患者的无复发生存期(RFS)。次要结局包括一年内疾病复发、手术时长、术后住院时间和并发症发生率。通过适当的检验进行统计分析,将P < 0.05的阈值定义为具有统计学意义。
与cTURBT队列相比,cESD-TURBT队列的无复发生存期延长,中位随访时间为775天(四分位间距[IQR] 414 - 1040)。cESD-TURBT队列的复发率为18.6%(22/118),而cTURBT队列的复发率为39.1%(41/105),对数秩检验风险比为0.49(95% CI 0.29 - 0.82;p = 0.0053)。此外,cESD-TURBT术后并发症少于cTURBT,显著降低了诸如闭孔反射等并发症的发生率(1.7%对8.6%,p = 0.03)。手术时间差异无统计学意义,cESD-TURBT为49.0 ± 21.0分钟,cTURBT为44.3 ± 23.8分钟(p = 0.127)。
我们的分析表明,与cTURBT相比,cESD-TURBT显著降低复发率且术后并发症更少。我们的研究表明,cESD-TURBT在膀胱肿瘤切除方面优于cTURBT。